Literature DB >> 35029168

Reply to Chen and Vitetta.

Francesco Violi1, Pasquale Pignatelli1,2, Alessandra Oliva3, Vittoria Cammisotto4.   

Abstract

Entities:  

Year:  2022        PMID: 35029168      PMCID: PMC8806381          DOI: 10.14309/ctg.0000000000000448

Source DB:  PubMed          Journal:  Clin Transl Gastroenterol        ISSN: 2155-384X            Impact factor:   4.396


× No keyword cloud information.
We thank Drs Chen and Vitetta for the interesting comment to our study regarding the detection of low-grade endotoxemia in patients with coronavirus disease-19 (COVID-19) (1,2). We found that in COVID-19 patients, lipopolysaccharides (LPS) was significantly higher than in controls (median values 50 vs 13 pg/mL, P < 0.001, respectively) and associated with an enhanced risk of venous and arterial thrombosis. The increase of circulating LPS may have different explanation, but enhanced gut permeability is likely to play a major role. Thus, patients with COVID-19 displayed a significant correlation between serum LPS and zonulin, an indirect marker of gut permeability (3). As outlined by Chen and Vitetta, commensal bacteria greatly contribute to gut barrier integrity, thereby changes of gut microbiota (dysbiosis) may affect gut permeability and enhance LPS translocation into systemic circulation. This hypothesis is consistent with experimental studies where influenza virus elicited gut dysbiosis (4) and with a study in patients with community acquired pneumonia, where we found enhanced circulating LPS with a significant correlation with zonulin (5). It seems that changes in gut permeability-mediated LPS translocation into systemic circulation is a common feature of lung infections. Systemic inflammation related to the underlying infection has been suggested to play a role (4). However, an important caveat of these studies is the lack of direct evidence of enhanced gut permeability in patients with lung infections. Therefore, a direct methodology using, for instance, quantification of the urinary excretion of orally administered macromolecules, such as polyethylene glycol and disaccharides (lactulose or cellobiose) in combination with monosaccharides (mannitol or rhamnose) needs to be used to support the existence of such lung-gut axis. Altogether, these data indicate that low-grade endotoxemia is a common feature of lung infections, but further study is necessary to examine its impact on clinical outcomes in short- and long-term follow-up.

CONFLICTS OF INTEREST

Guarantor of the article: Francesco Violi, MD. Specific author contributions: F.V. conceptualized and wrote the draft. P.P., A.O., and V.C. revised and edited the article. Financial support: None to report. Potential competing interests: None to report.
  5 in total

1.  Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease.

Authors:  A Fasano; T Not; W Wang; S Uzzau; I Berti; A Tommasini; S E Goldblum
Journal:  Lancet       Date:  2000-04-29       Impact factor: 79.321

2.  Low-grade endotoxemia, gut permeability and platelet activation in community-acquired pneumonia.

Authors:  Roberto Cangemi; Pasquale Pignatelli; Roberto Carnevale; Simona Bartimoccia; Cristina Nocella; Marco Falcone; Gloria Taliani; Francesco Violi
Journal:  J Infect       Date:  2016-06-08       Impact factor: 6.072

Review 3.  Respiratory Viral Infection-Induced Microbiome Alterations and Secondary Bacterial Pneumonia.

Authors:  Shigeo Hanada; Mina Pirzadeh; Kyle Y Carver; Jane C Deng
Journal:  Front Immunol       Date:  2018-11-16       Impact factor: 7.561

4.  Gut Dysbiosis Could Be a Major Factor for the Effects of Low-Grade Endotoxemia in COVID-19 Comment on: Low-Grade Endotoxemia and Thrombosis in COVID-19.

Authors:  Jiezhong Chen; Luis Vitetta
Journal:  Clin Transl Gastroenterol       Date:  2022-01-12       Impact factor: 4.396

5.  Low-Grade Endotoxemia and Thrombosis in COVID-19.

Authors:  Alessandra Oliva; Vittoria Cammisotto; Roberto Cangemi; Domenico Ferro; Maria Claudia Miele; Massimiliano De Angelis; Francesca Cancelli; Pasquale Pignatelli; Mario Venditti; Francesco Pugliese; Claudio Maria Mastroianni; Francesco Violi
Journal:  Clin Transl Gastroenterol       Date:  2021-06-04       Impact factor: 4.488

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.